Is Low-Dose Testosterone Safe During Pregnancy?

The Short Answer: Testosterone Is Contraindicated in Pregnancy

Stop here if you are pregnant or actively trying to conceive. Low-dose testosterone, whether prescribed as a compounded transdermal cream, gel, or pellet for female sexual health, must not be used during pregnancy. The FDA prescribing information for testosterone products classifies testosterone as contraindicated in pregnant women because androgen exposure during critical windows of fetal organogenesis can permanently alter the development of a female baby's external genitalia.

This applies to every formulation: FDA-approved injectable or gel products, and compounded transdermal preparations that are popular for female HSDD. Compounded testosterone carries no separate regulatory exemption from this risk.

Why This Matters for Women Specifically

Most of the published safety literature on testosterone in pregnancy focuses on conditions like congenital adrenal hyperplasia (CAH), where the fetus itself overproduces androgens. But the underlying teratogenic mechanism is the same whether excess androgen comes from the fetus or from an exogenous source the mother is applying to her skin. A female fetus exposed to supraphysiologic androgens during weeks 7 to 12 of gestation, the window when external genitalia are sexually differentiated, can develop virilized external genitalia including clitoral enlargement and labioscrotal fusion [1].

What the Evidence Actually Shows

The evidence base is composed largely of case reports, animal studies, and data extrapolated from CAH pregnancies rather than controlled trials of testosterone therapy in pregnant women. There are no randomized or observational cohort studies specifically examining compounded low-dose transdermal testosterone use in pregnant women. This is an important gap to name honestly. What exists:

• Animal data: Testosterone administered to pregnant animals at doses below those producing maternal toxicity caused virilization of female offspring, as documented in multiple preclinical species referenced in FDA labeling [2].
• Human case reports: Maternal androgen excess from any source, including exogenous testosterone, is associated with female fetal virilization in case series published in peer-reviewed journals [3].
• CAH extrapolation: Studies of female fetuses exposed to endogenous androgen excess in CAH pregnancies demonstrate the same phenotype, providing a biologically plausible human model [4].

The honest summary: there are no controlled human studies because running them would be unethical. The prohibition rests on sound mechanistic evidence and case data, not a precautionary absence of data.

Who Is Being Prescribed Low-Dose Testosterone, and Why This Collision Matters

Low-dose testosterone for women is currently prescribed off-label, most commonly for HSDD in postmenopausal women. The Endocrine Society clinical practice guideline on female androgen deficiency does not endorse a specific female "deficiency" diagnosis but acknowledges off-label testosterone use for HSDD in postmenopausal women. The International Society for the Study of Women's Sexual Health (ISSWSH) and the Global Consensus Position Statement from 2019 also specifically limit their recommendation to postmenopausal women [5].

Despite this framing, compounded testosterone is prescribed across a broader population in clinical practice, including women in perimenopause, women with surgical menopause at younger ages, and, less commonly, premenopausal women with low libido. Any woman who is premenopausal and taking testosterone is, by definition, potentially at risk of pregnancy unless she is using reliable contraception or has confirmed permanent contraception.

Life Stage Breakdown

Reproductive years (roughly ages 18 to 45, cycling normally) You may be prescribed testosterone off-label by a practitioner for low libido. If you have not reached menopause, you can still conceive. The combination of potentially reduced libido plus any cycle irregularity testosterone might cause can make it harder to track fertility accurately. Reliable contraception is non-negotiable while taking testosterone in this life stage.

Perimenopause Cycle irregularity is common in perimenopause. Many women assume they are no longer fertile when cycles become unpredictable, but pregnancy remains possible until you have had 12 consecutive months without a menstrual period. ACOG Practice Bulletin guidance notes that contraception should be continued until menopause is confirmed. Do not assume testosterone is safe to use without contraception just because your periods are irregular.

Post-menopause (confirmed) This is the life stage for which off-label testosterone use for HSDD has the most clinical support. At confirmed post-menopause, pregnancy is not a concern. The risk calculus shifts: the teratogenic risk disappears, but questions about cardiovascular, breast, and metabolic effects over long-term use remain open questions (discussed below).

Trying to conceive Testosterone is incompatible with attempting pregnancy. Discontinue before the cycle in which you plan to conceive. The clearance half-life of transdermal testosterone is short (roughly 70 minutes for free testosterone, though tissue depot effects with compounded creams may extend exposure), but no safe washout duration has been formally established in women. Discuss timing with your prescriber.

Pregnancy Stop immediately. Inform your obstetric provider that you were using testosterone and when you stopped.

Pregnancy and Lactation Safety: The Required Detail

Pregnancy

Testosterone is listed by the FDA as contraindicated in pregnancy, reflecting the highest level of caution for a known or strongly suspected human teratogen in this context [2]. The mechanism of harm is androgen receptor-mediated virilization of female fetal external genitalia. The external genitalia of a female fetus are androgen-sensitive between approximately gestational weeks 7 and 12. Exposure during this window is associated with the highest risk of anatomical virilization. Exposure later in pregnancy may affect other androgen-sensitive tissues including the brain, though human data on behavioral effects from maternal testosterone therapy are absent.

Male fetuses are not typically virilized beyond their expected development by modest androgen exposure, but this does not mean the risk to the pregnancy is zero. Placental transfer of testosterone occurs. One primary literature review examining placental transfer kinetics of sex steroids confirmed that testosterone crosses the human placenta.

If you discover you are pregnant while using testosterone, stop immediately and contact your obstetric provider. The timing of exposure relative to gestational age will guide counseling. An anatomy ultrasound at 18 to 20 weeks can assess fetal external genitalia. If fetal virilization is identified, you should be referred to a maternal-fetal medicine specialist.

The table below summarizes the pregnancy risk framework for testosterone exposure by gestational window, synthesized from the teratology and androgen biology literature.

| Gestational Window | Primary Fetal Risk | Human Evidence Level | |---|---|---| | Weeks 7 to 12 | Virilization of female external genitalia (clitoral enlargement, labioscrotal fusion) | Case reports, CAH extrapolation | | Weeks 13 to 24 | Possible effects on androgen-sensitive brain regions; less genital risk | Animal data only | | Third trimester | Limited anatomical risk; pharmacologic effects uncertain | Extrapolation only | | Any trimester | Placental transfer confirmed; no trimester is established as safe | Primary literature [6] |

Lactation and Breastfeeding

Testosterone transfers into human breast milk. The NIH LactMed database entry for testosterone states that testosterone is found in breast milk and advises that women taking exogenous testosterone should not breastfeed [7]. The concern is two-fold: direct transfer of testosterone to the infant through milk, and potential suppression of lactation, since androgen excess can reduce milk supply by interfering with prolactin activity.

For a female infant, even small androgen exposures through breast milk during early postnatal life carry theoretical risks to androgen-sensitive developing tissues, though quantitative dose-response data in humans are not available. The absence of data is not reassurance. Avoid testosterone while breastfeeding.

If you are postpartum and considering testosterone for HSDD or libido concerns that emerged after delivery, wait until you have fully weaned your infant and your hormonal status has restabilized. Many postpartum libido concerns resolve as estrogen and prolactin normalize after weaning, so a watchful waiting approach before initiating any androgen therapy is reasonable.

Contraception Requirement

Any woman of reproductive potential who is prescribed testosterone must use reliable contraception. The bar is not "I am not actively trying to get pregnant." It is confirmed, consistent contraception. Options that are compatible with concurrent testosterone use include:

• Copper intrauterine device (IUD), which provides highly effective non-hormonal contraception
• Levonorgestrel IUD (hormonal IUDs do not significantly raise androgen levels and are acceptable)
• Tubal ligation or other confirmed permanent contraception
• Combined hormonal contraceptives or progestin-only methods, though some practitioners prefer avoiding additional hormone overlap, so discuss with your provider

Barrier methods alone are less reliable and generally not recommended as the sole contraceptive strategy when taking a known teratogen.

What Low-Dose Testosterone Does in the Female Body (And Why Monitoring Matters)

Understanding the pharmacology helps explain why the pregnancy risk is real even at the low doses used for HSDD.

Pharmacokinetics in Women

Women have much lower baseline testosterone levels than men, with premenopausal women typically ranging from 15 to 70 ng/dL for total testosterone [8]. Compounded transdermal testosterone for HSDD typically targets levels in the upper premenopausal physiologic range, around 150 to 300 pg/mL free testosterone or a total testosterone of 10 to 35 ng/dL above baseline depending on the protocol. Because the therapeutic window is narrow and individual absorption varies substantially with transdermal formulations, serum levels can inadvertently rise above the intended range.

Excess testosterone is aromatized to estradiol in adipose tissue and also undergoes 5-alpha reduction to dihydrotestosterone (DHT), a more potent androgen. DHT does not aromatize and has higher androgen receptor affinity. Both excess testosterone and its metabolites can cross the placenta.

Monitoring in Non-Pregnant Women

If you are taking testosterone for HSDD and are not pregnant, your provider should monitor:

• Total and free testosterone levels every 3 to 6 months
• Hematocrit (androgen-stimulated erythropoiesis can raise red blood cell count)
• Signs of virilization (acne, hair growth changes, voice changes, clitoral enlargement) at each visit
• Lipid panel annually, given possible androgen effects on HDL cholesterol

The Global Consensus Position Statement on testosterone use in women recommends maintaining serum testosterone levels within the normal premenopausal range and monitoring for androgenic side effects [5]. Exceeding this range increases both your side-effect burden and, if pregnancy occurs, the concentration available to cross the placenta.

Female-Relevant Conditions That Intersect With Testosterone Use

Several conditions common in women create particular complexity around testosterone therapy.

PCOS and Androgen Excess

Women with polycystic ovary syndrome (PCOS) often already have elevated endogenous androgens. Adding exogenous testosterone to an already androgen-replete system raises the risk of further elevating levels into a range that could harm a fetus. PCOS also affects fertility, sometimes creating the paradox of a woman who believes she is unlikely to conceive but is not using contraception. PCOS is not reliable contraception. Women with PCOS who are prescribed testosterone for libido concerns must use contraceptive protection.

Female Pattern Hair Loss

Some compounded testosterone protocols are prescribed for female pattern hair loss (FPHL), though the evidence base here is weak and androgen-sensitive hair loss can actually worsen with testosterone. If you are using testosterone for FPHL and are of reproductive age, the same contraception requirement applies. ACOG guidance and dermatology guidelines do not support testosterone as a standard treatment for FPHL, and the risk-benefit ratio in reproductive-age women is unfavorable.

Perimenopause and Surgical Menopause

Women who have undergone bilateral oophorectomy before natural menopause experience an abrupt drop in testosterone (the ovaries produce roughly 25% of circulating testosterone in premenopausal women). If oophorectomy was done alongside hysterectomy, pregnancy is impossible and the teratogen concern is moot. If oophorectomy was done with uterine preservation (rare, but possible), pregnancy cannot occur without ovaries, so again the teratogen risk does not apply. For women with intact reproductive anatomy in perimenopause, see the life stage section above.

Postpartum Libido and HSDD

Postpartum HSDD is common and often resolves with time, weaning, and relationship factors. Testosterone is not appropriate while breastfeeding and is not established as safe or effective for postpartum HSDD in the literature. The ISSWSH position on female androgen therapy does not include postpartum women in any treatment recommendation [9].

What to Do If You Were Taking Testosterone and Just Found Out You Are Pregnant

This scenario is more common than many clinicians expect, particularly with compounded preparations that may be prescribed with less reproductive counseling than FDA-approved drugs.

1. Stop testosterone immediately.
2. Call your OB-GYN or midwife today, not at your next scheduled appointment.
3. Tell them the dose you were using, the formulation (cream, gel, pellet), and the date you stopped.
4. Ask about the timing of your last dose relative to the gestational age of your pregnancy, particularly whether your exposure overlapped with weeks 7 to 12.
5. Plan for a detailed anatomy ultrasound at 18 to 20 weeks to assess fetal external genitalia.
6. If concerns arise on ultrasound, ask for referral to maternal-fetal medicine (MFM).

Unintended pregnancy while on testosterone may be under-reported. A 2020 ACOG committee opinion on medication safety in pregnancy underscores the importance of counseling reproductive-age women about teratogenic medications before prescribing [10]. If your prescriber did not discuss contraception requirements with you when they started you on testosterone, that is a gap in care. You can ask for this conversation now.

Safer Alternatives by Life Stage

If you are trying to improve sexual desire or are dealing with HSDD, options that are compatible with pregnancy attempts or breastfeeding include:

During pregnancy or breastfeeding:

• Pelvic floor physical therapy for sexual pain contributing to low desire
• Sex therapy or couples therapy addressing relational or psychological factors
• No pharmacologic options for HSDD are established as safe in pregnancy or lactation

Reproductive years (not pregnant, using contraception):

• Addressing underlying contributors: sleep, relationship quality, depression, medications that suppress libido (especially SSRIs and oral contraceptives with high progestin potency)
• Flibanserin (Addyi) is approved for premenopausal HSDD but carries its own contraindications and is not compatible with alcohol; it is also not studied in pregnancy
• Testosterone off-label with strict contraception monitoring, if the prescriber and patient have had a full informed consent conversation

Post-menopause (confirmed):

• Testosterone off-label as per the Global Consensus Position Statement, with monitoring
• Ospemifene for dyspareunia contributing to desire concerns
• Local vaginal estrogen for GSM-related symptoms affecting sexual function

Evidence Gaps: What We Do Not Know

Women have been systematically excluded from androgen research in ways that leave real clinical gaps.

The pharmacokinetic behavior of compounded transdermal testosterone in pregnant women, including placental transfer rates at therapeutic female doses, has not been studied. Washout periods before conception have not been established. Long-term neurodevelopmental outcomes in children born after first-trimester testosterone exposure are unknown. The dose-response relationship between maternal testosterone level and fetal virilization severity has not been characterized in humans.

A 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism explicitly noted that the evidence base for female testosterone therapy is composed predominantly of short-term trials in postmenopausal women and that generalization to reproductive-age women is not supported by direct data [5]. This honesty matters. The contraindication in pregnancy is clear. The fine-grained details of degree of risk by dose and timing remain unstudied.